KGP94: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 25234575 |
SCHEMBL ID | 6337731 |
MeSH ID | M0584793 |
Synonym |
---|
[(e)-[(3-bromophenyl)(3-hydroxyphenyl)methylidene]amino]thiourea |
kgp94 |
gtpl6533 |
SCHEMBL6337731 |
HY-118762 |
MS-25407 |
1131456-28-4 |
kgp 94 |
kgp-94 |
CS-0068464 |
[(z)-[(3-bromophenyl)-(3-hydroxyphenyl)methylidene]amino]thiourea |
KGP94 is a potent, selective, and competitive inhibitor of the lysosomal endopeptidase enzyme (Cathepsin L) Currently in preclinical trials for the treatment of metastatic cancer.
Excerpt | Reference | Relevance |
---|---|---|
"KGP94 is a potent, selective, and competitive inhibitor of the lysosomal endopeptidase enzyme (Cathepsin L) currently in preclinical trials for the treatment of metastatic cancer, which is a leading cause of cancer-associated death. " | ( An efficient and concise synthesis of a selective small molecule non-peptide inhibitor of cathepsin L: KGP94. Munikishore, R; Wang, LL; Zhang, S; Zhao, QS; Zuo, Z, 2021) | 2.28 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |